Choosing the best hit-finding approach results in optimal candidates and increased efficiency. This white paper shows how to make that decision.
Hit identification is the bedrock of drug discovery programs and a key step on the path to clinical success. Companies that select the most appropriate approach for their project parameters at that early stage are rewarded with optimal candidates and increased downstream efficiency. Yet, in the complex, evolving hit identification landscape, there are pitfalls that can expose companies to significant risks.
The risks and opportunities make one initial question critical to answer: How do you choose the best hit-finding approach and technologies for your program? This white paper answers the question, covering topics such as:
Offered Free by: Charles River Laboratories
See All Resources from: Charles River Laboratories





